The European Medicines Agency (EMA) is working to facilitate decentralized clinical trials (DCTs) in the EU. DCTs are a type of clinical trial that uses remote monitoring and other technologies to allow patients to participate in trials from their homes or other convenient locations. This approach has the potential to make clinical trials more accessible to a wider range of patients, and to reduce the cost and time of drug development.
The U.S. Food and Drug Administration (FDA) is leading the charge in transforming the landscape of clinical trials. With their recent release of a draft guidance, the FDA is actively supporting decentralized clinical trials (DCTs) for drugs, biologics, and devices.
Home healthcare has become an essential component of decentralized clinical trials, offering several benefits for patients, researchers, and sponsors. In this blog post, we explore the advantages of home healthcare in decentralized clinical trials, including improved patient engagement, data quality, cost savings, and better patient safety.
Learn about the benefits of decentralized clinical trials (DCTs) for sponsors, including improved patient recruitment and retention, increased efficiency and reduced costs, more realistic results, better safety monitoring, and enhanced data quality.
Discover how DCTs are revolutionizing clinical research and improving patient participation, efficiency, and safety.
Discover the benefits of decentralized clinical trials (DCTs) for study sites in our latest blog post. From increased patient access to reduced costs and streamlined data collection, DCTs offer several advantages that can improve your clinical research process. Learn more now.